Drug Trial Radar · NCT05434156
ELE-101 Safety & Tolerability Study in Healthy Participants and Patients With Depression
Last checked: Nov 19, 2026Latest source record: Feb 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
84
Planned (sponsor's estimate)
Start
Oct 27, 2022
Primary completion
Dec 2025
Study completion Mar 2026
Sponsor
- Lead sponsor
- Eleusis TherapeuticsIndustry
- Sponsor type
- Industry
- Collaborators
- Beckley Psytech Limited
- First posted
- Jun 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A study to assess the safety and tolerability of a drug called ELE-101 and see how the body absorbs and removes the drug and how it affects the body in healthy adult participants (Part 1) and in patients with depression (Part 2).
Conditions
- Healthy Volunteers
- Major Depressive Disorder
- Depression
Interventions
ELE-101Drug
ELE-101 solution for intravenous infusion
ELE-101 PlaceboDrug
ELE-101 placebo matching solution for intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Percentage of participants with at least one safety eventTime frame: Baseline up to Day 8
- Part 2: Subjective Drug Intensity RatingsTime frame: pre-dose and at multiple time-points up to 24 hours post-dose
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
MAC Clinical Research
Liverpool, United Kingdom
MAC Clinical Research
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.